

WILL HE BE WEARING CHILDREN'S CLOTHES WHEN HE'S A 'GROWN-UP'?

Prescribing Information

Presentation A vial of sterile lyophilised powder of somatrem corresponding to 4IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2ml ampoule of water for injections for use in the reconstitution of the injection.

Uses The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

Dosage and Administration
Route of administration By intramuscular injection. **Recommended dosage** The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

Contra-indications, warnings, etc Only patients with unfused epiphyses should be treated. Diabetes mellitus. **Precautions** Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. **Side-effects** Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However as with pituitary derived hormone only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

Package Quantities Combined package containing one vial of somatrem 4 IU and one ampoule of 2ml water for injections.

Price NHS Price £28.

Further Information Somatrem is the British Approved Name for methionyl human somatotropin.

Product Licence Number 0022/0060

KabiVitrum Limited, Kabi-Vitrum House, Riverside Way, Uxbridge, Middx UB8 2YF.

Product Authorisation Number 187/28/1

Elire KabiVitrum, Cahill May Roberts Ltd, P.O. Box 1090, Chapelizod, Dublin 20.



Somatonorm® (somatrem)

is successfully changing the outlook for this child and thousands like him suffering from short stature caused by growth hormone deficiency (GHD).

With early diagnosis and treatment, GHD children can achieve a normal adult height.

For the past two decades, KabiVitrum has pioneered growth hormone research.

The introduction of Somatonorm ensures that, for the first time, sufficient growth hormone is available to treat all GHD children.



HE WANTS TO GROW. KabiVitrum CAN HELP HIM.

**UNIVERSITY OF LONDON
INSTITUTE OF PSYCHIATRY/INSTITUTE OF CHILD
HEALTH**


**DIPLOMA IN CHILD AND ADOLESCENT
PSYCHIATRY
AN INTERNATIONAL COURSE**

A one year course leading to a Diploma in Child and Adolescent Psychiatry will start in January 1988. This annual course is run jointly in London by the Institute of Psychiatry and the Institute of Child Health. It covers diagnosis and treatment of children and adolescents with psychiatric disorders including those with physical illness and chronic handicap; assessment of community needs in relation to Child Mental Health, with a view to planning or implementing psychiatric services in the participant's own country; teaching and training medical and paramedical workers. The course will be particularly suitable for paediatricians and psychiatrists intending to set up or work in child mental health services in developing countries. Good English essential.

Course Teachers will include Dr A Bentovim, Professor P Graham, Dr R Howarth, Dr P Howlin, Dr R Landsown, Dr B Lask, Dr N Richman, Professor M Rutter, Dr E Taylor, Dr S Wolkind, Dr W Yule.

Further details available from: Dr S Wolkind, Children's Department, Maudsley Hospital, Denmark Hill, London SE5 8AF.

Applications should be returned by 1 September 1987.



**This publication
is available in
microform.**

University Microfilms
International reproduces this
publication in microform:
microfiche and 16mm or
35mm film. For information
about this publication or any
of the more than 13,000 titles

we offer, complete and mail the coupon to: University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106. Call us toll-free for an immediate response: 800-521-3044. Or call collect in Michigan, Alaska and Hawaii: 313-761-4700.

☐ Please send information about these titles:

Name _____
Company/Institution _____
Address _____
City _____
State _____ Zip _____
Phone (____) _____

**University
Microfilms
International**

**Paediatric Perspectives on
Epilepsy**

Edited by EUAN ROSS

Paediatric epilepsy is a highly complex disorder which can represent a considerable challenge to the clinician. In recent years, however, there has been marked progress in the understanding of the various types of childhood epilepsy and their causation, as well as major advances in treatment, particularly involving anticonvulsant drugs which control seizures better than before, with fewer side effects. The subject is now attracting considerable interest among researchers and clinicians, and this book attempts to present a state of the art picture based on their latest findings.

September 1985 176pp 0471908177 £18.40/\$32.40

All About Adolescence

C.G.D. BROOK

This book is intended to provide an authoritative and up to date account of the various changes of adolescence and an explanation of the more common problems which may be encountered. Its practical, uncomplicated approach and highly readable style will make it an invaluable source of guidance and advice not only for medical practitioners in a wide variety of different specialities, nurses and social workers, but also for adolescents themselves, and their families.

November 1985 160pp 0471908606 £6.50/\$11.44

**Research in Preventive
Community Nursing Care**

Edited by ALISON WHILE

This collection of studies on health care and visiting will be of interest to all health visitors, midwives and social workers. It reflects the importance of the welfare of young children and their parents, in the studies on prophylactic care, the role of parental support in family visiting, and the perceptions of the Health Visitor in cases of child abuse.

Series: Developments in Nursing Research, Volume 4

October 1986 242pp 047191102X £9.95/\$16.95

**Paediatric Infectious Diseases
in Arab Countries**

Edited by ABDELAZIZ Y. ELZOUKI

Presents state-of-the-art information on the epidemiology, etiology and management of infectious diseases common in Arab children, and includes important topics such as paediatric infections, diarrheal diseases, streptococcal infections and their sequelae, neonatal infection, immunization and so on.

March 1987 approx. 300pp 0471911208 £30.00/\$46.20

John Wiley & Sons Ltd

Baffins Lane, Chichester, Sussex PO19 1UD, England

John Wiley & Sons
Chichester New York Brisbane Toronto Singapore

Effective asthma control in the pre-school child



Intal
Sodium Cromoglycate BP
Nebuliser Solution
right from the start

Prescribing Information

Presentation Ampoules containing Sodium Cromoglycate BP 20mg in 2ml sterile aqueous solution.
Uses Preventive treatment of bronchial asthma. Also prevents the bronchoconstriction caused by exercise, cold air and chemical irritants. **Dosage and Administration** Since Intal Nebuliser Solution therapy is preventive, it is important that regular dosage is maintained, as distinct from intermittent use to relieve symptoms. Adults and children: the contents of one ampoule are administered by nebulisation using a suitable power-operated nebuliser four

times daily. In severe cases frequency of administration may be increased to 5 or 6 times daily. **Contra-indications, Warnings etc.** There are no specific contra-indications. Intal Nebuliser Solution must not be given by injection. **Side effects** Occasional irritation of the throat and in rare cases severe broncho-spasm, have been reported with powder forms of Sodium Cromoglycate. **Basic NHS Cost and Product Licence Number** £9.43 for 48 x 2ml ampoules PL 0113/0068
* Registered trade mark.

FISONS

Pharmaceuticals

FISONS plc - PHARMACEUTICAL DIVISION 12 Derby Road, Loughborough, Leicestershire LE11 0BB

Epilim[®]

sodium valproate

Presentation 1. Epilim 200 Enteric Coated. A lilac-coloured enteric coated tablet containing 200mg sodium valproate. **2.** Epilim 500 Enteric Coated. A lilac-coloured enteric coated tablet containing 500mg

sodium valproate. **3.** Epilim 100mg crushable tablets. A white scored tablet containing 100mg sodium valproate. **4.** Epilim Syrup. A red, cherry-flavoured syrup containing 200mg sodium valproate per 5ml. **5.** Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg sodium valproate per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be swallowed whole. **Monotherapy Adults:** Start at 600mg/daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2,500mg per day). **Children over 20kg:** Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day). **Children under 20kg:** 20mg/kg of body weight per day; in severe cases may be increased up to 40mg/kg day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contraindications, Warnings; Contra-indication:** Active liver disease. **Side effects:** Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents mainly occurred during the first 6 months of therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting, lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect: measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other anti-depressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence Numbers** Epilim 200 Enteric Coated 0623/0006. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016. **NHS Cost** Epilim 200 Enteric Coated 100 tablets, £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from: Labaz, Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

In a wide range of epilepsies



Epilim[®]

sodium valproate

helps to maintain the normality of life

European Journal of Pediatrics

Incorporating
ACTA PAEDIATRICA BELGICA

Volume 145 Number 6 December 1986 Last issue of this volume

The pioneers of pediatric medicine 453

Review

Kohlschütter and Hausdorf: Primary (genetic) cardiomyopathies in infancy 454

Editorial

Touwen: Very low birth weight infants 460

Original investigations

Calame et al.: Neurodevelopmental outcome of VLBW infants 461

Piekkala et al.: Infant mortality in a region of Finland, 1968-1982 467

Chen et al.: Brainstem auditory evoked potential in neurodegenerative diseases 471

Schmid and Largo: Visual acuity and stereopsis between 5 and 10 years 475

Frost and Parkin: Neurological and intellectual abnormalities in congenital hypothyroidism 480

Ranke et al.: Growth hormone-releasing factor in growth hormone deficiency 485

Vandenplas and Sacre: Neonatal IgE, family history, diet and cow's milk allergy 483

Büller et al.: Vitamin-K status beyond the neonatal period 496

Schmidt et al.: Low antithrombin III in neonatal shock 500

Gitzelmann and Hirsig: Infant dumping syndrome 504

Poulos et al.: Prenatal diagnosis of Zellweger syndrome 507

Jonckheer et al.: LAV/HTLV-III infection in children of African origin 511

Hirao et al.: Inhibition of lymphocyte DNA synthesis by Kawasaki disease plasma 517

Principi et al.: Amoxicillin twice daily in the treatment of otitis media 522

Steinkamp et al.: Renal function in cystic fibrosis 526

Christophe et al.: Kidney size monitoring by ultrasound 532

Meinecke et al.: The velo-cardio-facial (Shprintzen) syndrome 539

Hecht et al.: Foramen magnum stenosis in homozygous achondroplasia 545

Anmenti et al.: Infantile cystinosis and insulin-dependent diabetes mellitus 548

Tomomasa et al.: Virus-associated haemophagocytic syndrome 550

Walters et al.: Obstructive endocarditis in an immunodeficient infant 553

Short communications

Hunneman et al.: Homovanillic and 4-OH-3-methoxymandelic acid in plasma 555

Nigro et al.: Coxsackievirus B-6 infection and diabetes mellitus 557

Hauffa et al.: Preoperative lateralization of ACTH-producing pituitary microadenoma 559

Guerrieri et al.: Plasma zinc in children with chronic diarrhoea 563

Case reports

Querfeld et al.: Generalized amyloidosis secondary to xantho-granulomatous pyelonephritis 565

Lukusa et al.: Internal male pseudohermaphroditism in a 6 week old child 568

Gambon et al.: Megaloblastic anaemia in one of monozygous twins of a vegetarian mother 570

Nielsen et al.: Normal urinary mucopolysaccharide excretion in Hunter disease 572

Schneider et al.: Desquamative interstitial pneumonitis and alveolar lipoproteinosis 575

Letters to the editors

v. d. Heijden et al.: Intrauterine exposure to indomethacin 579

Leung: Cutaneous nodule resulting from blood-letting in neonates 579

Ouden: Author's reply 579

Lorini et al.: Nerve function, retinopathy and diabetes mellitus 580

Dorchy and Noel: Author's reply 580

Shinozaki et al.: Specific IgA coproconversion in rotavirus infection 581

Sadat-Ali et al.: Metabolic acidosis in osteogenesis imperfecta 582

Özsoylu: Androgens and hypoproliferating anaemia 583

Matsukura et al.: Infantile and childhood fibroelastosis in two siblings 584

Acknowledgement to our reviewers 585

Please see inside for complete table of contents



Subscription information: Volume 145 (6 issues) will appear in 1986. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: Approx. US \$ 335.00 including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tel. (201) 348-4033, Telex 023 125994.

All other countries: Annual subscription rate: DM 896.00 plus carriage charges. Volume price: DM 896.00, single issue price: DM 179.20 plus carriage charges. Airmail delivery on request only. Carriage charges for SAL (Surface Airmail Lifted) to Japan, India, Australia and New Zealand are available on request. Orders can either be placed with your bookseller or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Tel. (0)30/8207-1, Telex 183319.



Springer International



Pure innovation revealed

The range of human insulins from Nordisk and Wellcome



Full prescribing information available on request from either:-

Nordisk-UK
 Highview House
 Tattenham Crescent
 Epsom KT18 5QJ
 Tel. No: Burgh Heath (07373) 60621

The Wellcome Foundation Ltd.
 Crewe Hall
 Crewe
 Cheshire CW11UB
 Tel. No: Crewe (0270) 883151

Human
● INSULATARD
 (Isophane Insulin Injection [NPH], highly purified human insulin [emp])

Human
● VELOSULIN
 (Neutral Insulin Injection, highly purified human insulin [emp])

Human
● MIXTARD 30/70
 (Neutral suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection [NPH] - human insulin [emp])

Human
● INTARD 50/50
 (Neutral suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH] - human insulin [emp])

Human INTARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH]), HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50 are manufactured from highly purified human insulin (emp). **PRESENTATION** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. **USES** Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. **CONTRA-INDICATIONS AND WARNINGS** Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Intard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. **PHARMACEUTICAL PRECAUTION** Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. **LEGAL CATEGORY P BASIC NHS PRICE** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50: 10 ml vial £6.95. **PRODUCT LICENCE NUMBERS** Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Intard 50/50 3132/0040 and 0003/0214.